Global Bioprocess Automation Software Market 2026 – 2035

The market size of the global bioprocess automation software will be estimated at USD 1.67 billion in 2025 and is expected to grow between USD 1.90 billion in 2026 and about USD 6.19 billion by 2035 with a current CAGR of 14% during the period of 2026 to 2035.

The big reason for the increase in the bioprocess automation software market is the tremendous growth of the biopharmaceutical and biotechnology industries, which are always in need of precise, reproducible, and scalable production processes. The increased demand for biologics, biosimilars, vaccines, and the new techniques like cell and gene therapies has complicated the processes and made the manual operations slow and error-prone. As a result, biomanufacturers are opting for automation software to benefit from real-time monitoring, advanced process control, and centralized data management in their upstream and downstream operations.

Market Highlight

• North America had a market share of 43% and was the market leader in the bioprocess automation software market in 2025.

• The Asia Pacific is expected to grow at the highest CAGR during the years 2026-2035.

• By type, the process analytical technology segment held the largest revenue share in 2025 of over 30%.

• By application, the downstream processing segment captures the largest market share of 34% in 2025.

Significant Growth Factors

The bioprocess automation software market trends present significant growth opportunities due to several factors:

• Rising Adoption of Digitalization and Automation: The increasing acceptance of digitalization and automation is the primary factor that propels the growth of the bioprocess automation software market, because the pharmaceutical and biotechnological industries are gradually moving towards the modern and simplified complex production techniques. The use of digital platforms allows for instant data collecting, main process controlling, and perfect joining of upstream and downstream bioprocesses, which results in a great decrease in manual input and mistakes made by humans. Automation software is a plus for manufacturing, as it leads to process uniformity, reproduces the quality of a batch to be the same as the previous one, and increases the efficiency of the entire operation, which points to all production in the area of biologics and advanced therapies. Additionally, digitized bioprocesses are underpinned by advanced analytics, predictive modeling, and automated control techniques, which support data-driven decision-making, thus enabling the manufacturers to increase their yields and reduce their downtimes. While companies are facing stricter regulations from the government, digital automation has been found to support compliance by making sure that there are accurate electronic records, proper control and tracking of the process, and that the organization is always ready for audits. All these benefits combined are pushing the adoption of digitalization and automation to the next level and making bioprocess automation software an indispensable device for attaining efficient, scalable, and compliant biomanufacturing.

• Increasing Demand for Biopharmaceuticals and Biologics: The biopharmaceuticals and biologics demand is constantly increasing, which in turn triggers the growth of the bioprocess automation software market since these products require to be manufactured in a highly controlled, complex, and reproducible way. Monoclonal antibodies, vaccines, recombinant proteins, and cell- and gene-based therapies are among the biologics that depend on fluctuating biological systems where even the slightest adjustments in the process can alter the quality and the amount of the product. The demand for these therapies worldwide is increasing due to the rise of chronic diseases, the aging of the population, and the increase of precision medicine, so the manufacturers need to produce more and more while keeping strict quality standards. Bioprocess automation software allows for monitoring in real-time, control of processes with high precision, and implementation of uniformly executed workflows, thereby assisting the manufacturers in their efforts to improve consistency, minimize batch failures, and attain the necessary quality standards. The continuous flow of new biopharmaceuticals and biologics is thus a major factor driving the software's rapid adoption in both commercial and clinical production areas.

What are the Major Advances Changing the Bioprocess Automation Software Market Today?

• Cloud-Based & Hybrid Software Platforms: One of the most significant advancements that contributed to the growth of the bioprocess automation software market is the acceptance of cloud-based and hybrid software platforms, which provide the ultimate in scalability, flexibility, and accessibility for biomanufacturers. The usage of these systems enables manufacturers to monitor and supervise their sites remotely while controlling their operations from one place. This implies that teamwork and the process of making decisions become easier. The so-called hybrid models, with on-premise control combined with cloud-based analytics and data storage, have become highly attractive because they address the concerns over data security and compliance but still allow the use of advanced analytics and digital integration. Furthermore, the platforms eliminate the need for and the costs of maintenance of infrastructure, but they also help in rapid scale-up of production capacity. In addition, cloud computing has opened up avenues for AI, machine learning, and process analytics to be deployed in the manufacturing sector that in turn lead producers to better the output, lower the breakdown times, and adhere to the rules more. The rising digital transformation initiatives among biopharmaceutical firms have made cloud-based and hybrid software platforms become a vital factor in the future of efficient and data-driven bioprocessing automation. For instance, in April 2025, Culture Biosciences, a frontrunner in cloud-based biomanufacturing, officially introduced the Stratyx™ 250, the very first mobile bioreactor connected to the cloud and capable of providing biotech firms with unmatched flexibility, automation, and remote control of their processes.

• IoT-Enabled Smart Sensors: The bioprocess automation software market is experiencing a dramatic shift due to the implementation of IoT-enabled smart sensors, which have the capability of providing continuous and real-time monitoring of process parameters that are essential throughout the entire biomanufacturing operation. The sensors constantly monitor, at a very high frequency the various variables, which consist of temperature, pH, dissolved oxygen, pressure, and biomass, and transmit the data directly to the automation software platforms where it is immediately analyzed and controlled. The IoT-enabled sensors provide the most precise and up-to-date view of both upstream and downstream processes; therefore, manual sampling can be done less frequently, human error will be virtually eliminated, and the questions of consistency from one batch to the other will be resolved. Furthermore, the data from these sensors combined with the capabilities of advanced analytics and automation software promote the use of predictive maintenance and early fault detection, allowing manufacturers to quickly fix equipment problems before incurring costs due to prolonged downtime or loss of batches. In addition, the IoT-enabled smart sensors take care of data integrity and storage, thereby assuring regulatory compliance and quality assurance. The IoT-enabled smart sensors are becoming the main factor for biomanufacturers switching to the very connected and data-driven production environments to attain efficient, reliable, and scalable bioprocess automation solutions.

Category Wise Insights

By Type

Why Process Analytical Technology Lead the Market?

The process analytical technology segment held the largest revenue share in 2025 of over 30%. The integration of PAT with automation software offers nonstop checking, analyzing, and parameter adjusting of things like pH, temperature, and dissolved oxygen, thus securing the process and being on the safe side of the regulations. By mixing state-of-the-art sensors, data analytics, and machine learning algorithms, the PAT software supports the manufacturers in realizing the high process efficiency, low batch failures, and quick release times. The rising regulatory stress on Quality by Design (QbD) and real-time release testing has made the adoption of PAT-powered automation platforms even faster, and these platforms are now seen as key tools for the upcoming biomanufacturing.

The laboratory information management systems segment is growing at a rapid rate over the analysis period. The LIMS application streamlines the collection, storage, and processing of laboratory data throughout the entire bioprocessing process, reducing human errors and thereby increasing data reliability. When coupled with other automation solutions like MES and PAT, LIMS provides a fluent transfer of data from R&D to manufacturing, thus helping in making decisions instantly and quality control in an efficient way. The increasing emphasis on virtual labs as well as the requirement for a unified data system in the development of biological products are stimulating the demand for bioprocess automation solutions based on LIMS.

By Application

Why Downstream Processing Dominates the Bioprocess Automation Software Market?

The downstream processing segment captures the largest market share of 34% in 2025. The main reason behind the extensive growth of the bioprocess automation software market is the high emphasis on the efficiency and the recovery of products in downstream processing. The purification process comprising filtration, chromatography, and centrifugation is the most critical to getting the maximum yield and purity, and the software for automation aids in performing these operations through precision control, monitoring, and optimization. Besides, the combination of real-time data analytics and process control systems gives biomanufacturers the ability to remove variability, cut down manual actions, and secure quality in their batches. In addition, the rising intricacy of biologic and cell-based therapy production is prompting the adoption of automation not only for scaling up but also for getting the approval of regulatory bodies in downstream processing, which thus opens up their use in both commercial and clinical manufacturing settings.

The data management segment is expected to grow at the highest rate over the projected period. Bioprocessing produces vast amounts of complex data from many different sources, such as sensors, analyzers, and control systems; therefore, automation software with cutting-edge data management features acts as the main player in real-time information centralization, analysis, and visualization. Moreover, the trend towards more intelligent and connected bioprocessing environments is fueled by the increasing use of cloud-based platforms, AI-based data analysis, and integrated digital ecosystems, as these technologies boost manufacturers’ capacity to effectively manage process data throughout the cycle.

Report Scope

Regional Analysis

How Big is the North America Bioprocess Automation Software Market Size?

Its market size, in terms of North America bioprocess automation software, is projected to be USD 718 million in 2025 with a growth of about USD 2331 million in 2035 with a CAGR of 12.5% between 2026 and 2035.

Why did North America Dominate the Bioprocess Automation Software Market in 2025?

In 2025, North America will dominate the global market with an estimated market share of 43%. The regional expansion is owing to the presence of major players and its strategic initiatives. For instance, in January 2026, Verista, a provider of automation, compliance, and quality solutions for the life sciences sector, disclosed the acquisition of Integral Solutions. Integral Solutions, which is located in Columbus, Ohio, is an international supplier of engineering and validation services to the life sciences industry. As a result of this acquisition, Verista is able to add automation, engineering, project management, and validation to its already existing capabilities, which will allow the company to provide even broader support throughout the whole life cycle of regulated operations in life sciences. Further, the established healthcare infrastructure boosts the industry expansion in the region.

U.S. Bioprocess Automation Software Market Trends

In the North American region, the US leads the industry expansion over the projected period. In the U.S. biopharmaceutical industry, the tough regulations and compliance requirements demand strong software solutions in the areas of data integrity, traceability, and audit readiness, thus propelling market development even more. In addition, the transition to cloud-based and integrated digital platforms not only supports the deployment of scalable systems but also encourages multi-site operations, thus giving the flexibility of modern biomanufacturing strategies at low costs.

Why is Asia Pacific Experiencing the Fastest Growth in the Bioprocess Automation Software Market?

Asia Pacific is growing at the highest CAGR over the analysis period. The main factors driving the growth are the increasing biomanufacturing capabilities, the increasing production of biologics, and the supportive government policies that promote automation and digitalization. China, Japan, India, and South Korea are among the countries that allocate a lot of money to make their pharmaceutical industries up to date, and that causes the use of automation software to increase considerably. Moreover, the region's highly qualified bioprocess engineers and the booming of local biotech start-ups are the reasons for the demand for affordable and flexible automation platforms.

China Bioprocess Automation Software Market Trends

The Chinese market has an extremely fast-growing market. The government of China is behind initiatives like "Made in China 2025" and an increase in funding for R&D in biopharmaceuticals, which are the driving forces of bioprocess automation software adoption. Besides, an increasing number of local manufacturers are using MES and PAT systems to comply with international standards and to produce better quality products simultaneously. In addition to the rapid growth of biologics manufacturing in the country, a partnership with global automation firms has been another factor driving the digital transformation of the bioprocessing industry.

Why is Europe is growing at a significant rate in the Bioprocess Automation Software Market?

Europe holds the substantial market share over the projected period. The bioprocess automation software market in Europe is significantly supported by the strong biologics and biosimilars manufacturing base of the region along with the increasing requirement of GMP compliance and eco-friendly manufacturing. Companies located in Germany, France, and Switzerland are increasingly choosing integrated automation platforms for better process control, traceability, and, most importantly, operational efficiency. The European Medicines Agency (EMA) is also promoting the use of automated software in the pharmaceutical industry by making the digitization of quality assurance and data-based process validation its top priority.

UK Bioprocess Automation Software Market Trends

UK holds the dominant position in the Europe market. The major contributors to this growth are the increased expenditure on biopharma innovation and the increased number of state-of-the-art therapy manufacturing plants. The government's support of the industry 4.0 movement and digital manufacturing through the UK Life Sciences Vision program is also a factor in the use of MES, LIMS, and PAT systems. The growing number of biotech start-ups and CDMOs in need of scalable, compliant automation solutions is also contributing to the rapid uptake of software in the country.

Why is the Middle East & Africa Region is growing rapidly in the Bioprocess Automation Software?

The MEA region is growing at a steady rate over the projected period. The MEA region offers a rare mix of factors that are responsible for this growth. One of them, or more correctly, the first one is that the country’s healthcare infrastructure and biotechnology investments are soaring, thereby increasing the adoption of biomanufacturing technologies like automation software to support the local production of biologics and vaccines.

UAE Bioprocess Automation Software Market Trends

UAE is growing at the highest CAGR during the forecast period. The UAE's concentration on digital transformation and innovation among all sectors is speeding up the use of cloud-based services, IoT interconnectivity, and data analytics that enhance the visibility of operations and the quality of decisions.

Top Players in the Bioprocess Automation Software Market and Their Offerings

• Xeris Pharmaceuticals Inc.

• Teva Pharmaceuticals USA Inc.

• Novo Nordisk A/S

• Sun Pharmaceutical Industries Ltd.

• Recordati

• Debiopharm

• Novartis Pharmaceuticals Corporation

• Ipsen Biopharmaceuticals Canada Inc.

• Crinetics Pharmaceuticals Inc.

• Ionis Pharmaceuticals

• Camurus AB

• Pfizer Inc.

• Eppendorf SE

• Genedata AG

• Thermo Fisher Scientific Inc

• Sartorius AG

• Others

Key Developments

Bioprocess automation software market has experienced considerable changes in the last two years as the market players are trying to diversify their technological aspects and develop product portfolios using strategic approaches.

• In July 2025, Azenta Life Sciences made an addition to its IntelliXcap™ series with the M6 Semi-Automated Handheld Screw Cap Decapper. This M6 is specifically designed for 48-format external thread screw cap tubes, and it is aimed at laboratories looking for the convenience of manual processes and the advantages of full automation at the same time. The IntelliXcap M6 gives lab workers the ability to decap or recap a whole column of tubes in just seconds because it combines the accuracy of automation in a handheld device that is easy to use. The device provides the same torque to all caps, thereby minimizing variability, safeguarding sample integrity, and also reducing the ergonomic strain on the operator. (https://www.labmanager.com/azenta-launches-intellixcap-m6-to-improve-ergonomics-and-efficiency-in-48-format-tube-labs-34735)

• In January 2026, Hiden Analytical has made a significant improvement to its SIMS Workstation line by introducing the Dual Polarity Simultaneous Detector. This innovation allows faster and more accurate surface analysis since the simultaneous detection of both positive and negative ions is performed in one run. Mass Spectrometry of Secondary Ions (SIMS) has become an indispensable technique in various industries like semiconductors, glass coatings, and thin films, among others, due to its great accuracy and sensitivity. The classical SIMS technique requires two separate measurements to get both ion polarities. Hiden Analytical has introduced a method that eliminates that double-dipping. (https://www.labmanager.com/revolutionising-materials-analysis-hiden-analytical-unveils-dual-polarity-sims-technology-34746 )

These strategic measures have enabled the companies to reinforce their competitive positions, increase the product line, boost their technological competencies and also seize growth opportunities in the fast-growing bioprocess automation software market.

The Bioprocess Automation Software Market is segmented as follows:

By Type

• Distributed Control Systems

• Manufacturing Execution Systems

• Supervisory Control and Data Acquisition

• Laboratory Information Management Systems

• Process Analytical Technology

By Application

• Upstream Processing

• Quality Control

• Downstream Processing

• Data Management

• Manufacturing Operations

By End Use

• Pharmaceutical & Biotech Manufacturers

• Academic & Research Institutions

• CDMOs & CMOs

• Contract Testing & Analytical Labs

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America